VEGFA and neoplasm: As compared with treatment with control Ig, bevacizumab inhibited tumor growth (P < 0.001), angiogenesis (P < 0.0001), and ascites (P < 0.001) in mice that had been administered recombinant VEGF189, but not in mice that had been administered VEGF+/+ sEVs (Fig. 8a–e).